InsidersTradesSigma
Total declarations
Companies
▲ Purchases (3 ops.)
▼ Sales (12 ops.)
Insider track record
CFODisclosed buys
3
Disclosed sells
12
T+90 hit rate
22%
T+90 mean return
-17.7%
Across 9 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the complete record of transactions filed by Henderson Molly, Chief Financial Officer. Director active across 2 companies, notably UroGen Pharma Ltd.. Cumulatively, 28 reports have been published. Breakdown: 3 buys · 12 sells. Total volume traded: €378k. Activity tracked since 17 May 2021. The latest transaction was disclosed on 7 April 2025 (Cession). Regulator: SEC (Form 4). All data is free.
Declarations28 total
3,678 shares@ US$4.55134.6% of flowCommon StockSEC:0000950170-25-052156:0
72,000 shares0Common StockSEC:0000950170-25-031042:0
6,583 shares@ US$6.588312.4% of flowCommon StockSEC:0000950170-25-008357:0
1,291 shares@ US$8.003.0% of flowCommon StockSEC:0000950170-24-139062:0
4,325 shares@ US$11.7213.9% of flowCommon StockSEC:0000950170-24-084182:0
7,500 shares0Common StoockSEC:0000950170-24-067548:0
3,435 shares@ US$11.1010.5% of flowCommon StoockSEC:0000950170-24-043385:0
6,307 shares@ US$7.753313.4% of flowCommon StockSEC:0001209191-24-002021:0
2,127 shares@ US$7.24154.2% of flowCommon StockSEC:0001209191-23-056288:0
22,500 shares0Common StockSEC:0001209191-23-054355:0
25,000 shares0Common StockSEC:0001209191-23-043162:0
25,000 shares@ US$1.006.6% of flowCommon StockSEC:0001209191-23-042455:0
1,960 shares@ US$11.41216.2% of flowCommon StockSEC:0001209191-23-034605:0
2,110 shares@ US$12.87447.5% of flowCommon StockSEC:0001209191-23-031647:0
3,439 shares@ US$7.276.8% of flowCommon StockSEC:0001209191-23-023749:0
2,032 shares@ US$8.53094.9% of flowCommon StockSEC:0001209191-23-016023:0
33,000 shares0Common StockSEC:0001209191-23-004337:0
2,159 shares@ US$9.606.0% of flowCommon StockSEC:0001209191-22-058627:0
7,500 shares0Common StockSEC:0001209191-22-048473:0
12,000 shares0Common StockSEC:0001209191-22-031085:0
6,000 sharesCommon StockSEC:0001209191-22-029446:0
Ideal exit: 7 Feb 2023 (T+270)
20,000 shares0Common StockSEC:0001209191-22-023561:0
666 sharesOrdinary SharesSEC:0001209191-22-006385
666 sharesOrdinary SharesSEC:0001209191-22-006385:0
5,000 sharesOrdinary SharesSEC:0001209191-21-067439
25 of 28 declarations
About Henderson Molly
Molly Henderson is the Chief Financial Officer of UroGen Pharma Ltd. and Phathom Pharmaceuticals, Inc. In these roles, she is responsible for financial management and strategy, contributing to the financial sustainability and growth of these biopharmaceutical companies.
